Active clinical trials for "Coronary Disease"

To use a new statistical method, the Logical Analysis of Data (LAD), to predict cardiac surgery risk.

To examine whether the prevalence of subclinical coronary and aortic atherosclerotic disease is different among Japanese in Japan, Japanese in Hawaii, and black and white Americans.

To examine biopsychosocial processes that might contribute to the associations among social dominance, gender, and cardiovascular reactivity,.

To develop and test a self-scored cardiovascular disease health risk appraisal.

To study psychosocial risk factors for coronary heart disease in Swedish women.

To investigate if neighborhood characteristics are related to disease risk in a multiethnic cohort.

The optimal antithrombotic treatment for Coronary Heart disease (CHD) patients combined with Atrial Fibrillation (AF) is unresolved at present. Although the European and American guidelines have given a hand for us, there is absence of real-world data on the safety and efficacy of antithrombotic therapy in Asian populations. Only a few clinical trials are available to guide difficult decision on antithrombotic therapy in patients with combined AF and CHD，the investigators highlight the need for the rapid development of clinical trials to close the large gaps in evidence. This research aims to know the real-world use of antithrombotic treatment and clinical prognosis in Coronary Heart Disease patients complicated with Atrial Fibrillation.

To compare hs-TnT levels after a cardiac stress test in patients with vs. patients without CAD To assess the level of post-exercise hs-TnT predicting CAD (using ROC-analysis) To determine the sensitivity, specificity and accuracy of this exercise-induced hsTopT level in predicting CAD, either alone or in relation to traditional patient-related and exercise test-related metrics

The study aims to evaluate the safety and efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with coronary artery disease . The primary endpoint is target lesion failure, a composite endpoint of cardiac death, target vessel related myocardial infarction and clinically-driven target lesion revascularization at 1 year follow-up.

The aim of this work is to assess the clinical significance of serum levels of neutrophil gelatinase-associated lipocalin (NGAL) to predict AKI in patients exposed to PCI.